GE Healthcare Acquires Zionexa
By Michael Dabaie
General Electric Co.'s healthcare business said it acquired
Zionexa, a company focused on in-vivo oncology and neurology
GE Healthcare said it aims to develop and bring to market
Zionexa's pipeline biomarkers, as well as the recently Food and
Drug Administration-approved positron emission tomography imaging
agent, Cerianna. Cerianna is used as an adjunct to biopsy for the
detection of estrogen receptor positive lesions to help inform
treatment selection for patients with recurrent or metastatic
Zionexa was formed in 2018 and headquartered in Aubiere, France.
The company employs 24 people in France and the U.S., all of whom
will transfer to GE Healthcare. GE Healthcare said it will hire
about 70 new dedicated employees within the company's U.S.
Pharmaceutical Diagnostics team.
Financial terms of the acquisition aren't being disclosed, the
Write to Michael Dabaie at firstname.lastname@example.org
(END) Dow Jones Newswires
May 06, 2021 09:36 ET (13:36 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.